CoChat

Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Objective The aim of this study was to investigate the efficacy and efficiency of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain. Of major interest were the evaluation of the influence the treatment had on pain and on quality of life as well as the subjective assessment of positive effects and side effects by the study participants. Methods The placebo-controlled double-blinded pilot study was divided into a 14 week cross-over period (two 4 week medication phases plus wash-out phases) followed by a 16 week medication switch period with free choice of the study drugs (drug A and drug B) by the study participants. The principal inclusion criterion was chronic therapy-resistant pain in causal relationship with a pathologic status of the skeletal and locomotor system. The study participants chose the dosage of the study drug themselves (between 1 und 4 capsules/day, in the case of nabilone this corresponds to (1/4)-1 mg/day). Pain intensity was assessed by a visual analogue scale (VAS), quality of life by the Mezzich and Cohen QOL-score. Results Altogether, 30 patients were included and analyzed. From the results, it is obvious that throughout the cross-over periods the nabilone treatment was superior (medians [25%-; 75%-percentiles]: nabilone/placebo): decrease of the average spinal pain intensity within the last 4 weeks (DeltaVAS) 0.9 [0.0; 2.0] / 0.5 [0.0; 1.7], decrease of the current spinal pain intensity (DeltaVAS) 0.6 [0.0; 2…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00508-006-0611-4

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Grotenhermer F (2001) Pharmakologie, Toxikologie und therapeutisches Potential von Cannabis und Cannabinoiden. Huber, Bern

Cited by

See all 96

Metadata

Authors
Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W.
Affiliations
  • Johannes Kepler University of Linz (AT)
  • Medical University of Vienna (AT)
Corresponding author
Pinsger, Martin
Venue
Wiener klinische Wochenschrift
Published
2006-06
Volume
118
Issue
11-12
Pages
327-335
ISSN
  • 0043-5325 (ISSN-L)
  • 1613-7671
OpenAlex
W1494478174
Cited by
96
References
26
Citations by year
2026: 2 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 14 · 2021: 7 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 3 · 2014: 2 · 2013: 3 · 2012: 6
FWCI
2.51
Type
journal article
Language
de
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Wiener klinische Wochenschrift (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
chronic pain, adjunctive therapy, treatment-resistant pain, spinal pain, headache, quality of life, pain intensity, adverse effects, crossover design, cost-effectiveness, patient satisfaction, physician satisfaction
MeSH terms
Cannabinoids, Chronic Disease, Double-Blind Method, Female, Humans, Male, Middle Aged, Pain, Pain Measurement, Quality of Life, Dronabinol, Anti-Anxiety Agents, Placebo Effect, Treatment Outcome, Chemotherapy, Adjuvant, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie. https://app.cochat.ai/papers/10.1007/s00508-006-0611-4
The paper
Pinsger, M., Schimetta, W., Volc, D., Hiermann, E., Riederer, F., & Pölz, W. (2006). Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen – eine randomisierte kontrollierte Studie. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-006-0611-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.